<PAGE>
Registration No. 333-
===============================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
------------
PANAX PHARMACEUTICAL COMPANY, LTD.
(Exact name of registrant as specified in its charter)
NEW YORK
(State or other jurisdiction of incorporation or organization)
13-3754005
(I.R.S. Employer Identification No.)
425 PARK AVENUE, 27TH FLOOR
NEW YORK, NY 10022
(Address of principal executive offices)
1993 STOCK OPTION PLAN
(Full Title of the Plan)
LEO SILVERSTEIN, ESQ.
BROCK, FENSTERSTOCK, SILVERSTEIN,
MCAULIFFE & WADE, LLC
ONE CITICORP CENTER - 56TH FLOOR
NEW YORK, NEW YORK 10022
(212) 371-2000
(Name, Address and Telephone Number of Agent for Service)
<PAGE>
<TABLE>
<CAPTION>
CALCULATION OF REGISTRATION FEE
===============================================================================
PROPOSED PROPOSED
TITLE OF MAXIMUM MAXIMUM
SECURITIES AMOUNT OFFERING AGGREGATE AMOUNT OF
TO BE TO BE PRICE PER OFFERING REGISTRATION
REGISTERED REGISTERED SHARE PRICE FEE
- -------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common Stock,
par value
$0.0001
per share 300,000 shs. $2.4375(1) $731,250 $221.59
- -------------------------------------------------------------------------------
Total 300,000 shs. $731,250 $221.59
===============================================================================
<FN>
(1) Calculated pursuant to Rule 457(h)(1) on the basis of the price at
which said common stock was traded on the Nasdaq SmallCap Market on
the day prior to the date of filing hereof.
</TABLE>
THIS REGISTRATION STATEMENT SHALL BECOME EFFECTIVE IMMEDIATELY UPON FILING AS
PROVIDED IN RULE 462 UNDER THE SECURITIES ACT OF 1933.
THE CONTENTS OF AN EARLIER REGISTRATION STATEMENT, FILE NO. 333-00922, IS
INCORPORATED HEREIN BY REFERENCE.
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Act of 1933,
the Registrant certifies that it has reasonable grounds to believe that it
meets the requirements for filing on Form S-8 and has duly caused this
Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of New York, State of New York, on June 13, 1996.
Panax Pharmaceutical Company, Ltd.
By: /s/ Dr. Taffy J. Williams
------------------------------
Dr. Taffy J. Williams
Chairman, President and Chief Executive Officer
----------------
KNOW ALL MEN BY THESE PRESENTS, that each person whose
signature appears below constitutes and appoints Dr. Taffy J. Williams, his
true and lawful attorney-in-fact, with power of substitution and
resubstitution, to execute in the name of such person, in his capacity as a
director or officer of Panax Pharmaceutical Company, Ltd., any and all
amendments to this Registration Statement on Form S-8 and all instruments
necessary or incidental in connection therewith, and to file the same with the
Securities and Exchange Commission, hereby ratifying and confirming all that
said attorney-in-fact, or his substitute, may do or cause to be done by virtue
hereof.
Pursuant to the requirements of the Securities Act of 1933,
this Registration Statement has been signed on June 13, 1997, by the following
persons in the capacities indicated.
<TABLE>
<CAPTION>
Signature Title Date
- --------- ----- ----
<S> <C> <C>
/s/ Taffy J. Williams Chairman of the June 13, 1997
- ----------------------------- Board, President and
Dr. Taffy J. Williams Chief Executive Officer
(Principal Executive Officer);
Director
<PAGE>
/s/ Tanya Akimova Vice President June 13, 1997
- ----------------------------- and Director
Dr. Tanya Akimova
/s/ J.R. LeShufy Vice President and June 13, 1997
- ----------------------------- Director
J.R. LeShufy
/s/ Bernard Nagelberg Vice President June 13, 1997
- ----------------------------- Director
Bernard Nagelberg
/s/ Leonid Shpilenya Director June 13, 1997
- -----------------------------
Dr. Leonid Shpilenya
</TABLE>
